Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.

The combined effect of heparin coating of cardiopulmonary bypass (CPB) circuits and reduced dose of systemic heparin on activation of the complement system and blood leukocytes was investigated in 19 patients undergoing coronary bypass surgery and randomly allocated to two groups. A heparin-coated CPB circuit together with a 50% reduction of the standard heparin dose were used for ten patients (HC group), and a standard CPB circuit with a standard heparin dose (300 IU/kg) for nine (C group). Significant rise in the levels of neutrophil-derived myeloperoxidase, lactoferrin and calprotectin were observed during CPB in both groups, but the total accumulated levels were significantly lower in the HC than in the C group (p < 0.05). Complement activation, assessed from levels of C3a and terminal complement complexes was similar in both groups. The lower levels of myeloperoxidase, lactoferrin and calprotectin during CPB in the HC group indicate that surface modification with end-point attached heparin enhances the biocompatibility of CPB.

[1]  I. Olsson,et al.  Myeloperoxidase and lactoferrin of blood neutrophils and plasma in chronic granulocytic leukaemia. , 2009, Scandinavian Journal of Haematology.

[2]  S. Thelin,et al.  Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. , 2008, Artificial organs.

[3]  J. van der Linden,et al.  Heparin coating reduces blood cell adhesion to arterial filters during coronary bypass: a clinical study. , 1993, The Annals of thoracic surgery.

[4]  W. van Oeveren,et al.  Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[5]  E. Fosse,et al.  Calprotectin and complement activation during major operations with or without cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[6]  B. Nilsson,et al.  Modification of the Complement Binding Properties of Polystyrene: Effects of End‐Point Heparin Attachment , 1993, Scandinavian Journal of Immunology.

[7]  S Westaby,et al.  Inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[8]  A. Røseth,et al.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. , 1992, Scandinavian journal of gastroenterology.

[9]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[10]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[11]  B. Nilsson,et al.  Generation of iC3 at the Interface between Blood and Gas , 1992, Scandinavian journal of immunology.

[12]  R. Davey,et al.  Changes in lymphocyte subpopulations as a result of cardiopulmonary bypass. The effect of blood transfusion. , 1991, The Journal of thoracic and cardiovascular surgery.

[13]  S. Hagl,et al.  The influence of extracorporeal circulation and hemoseparation on red cell deformability and membrane proteins in coronary artery disease. , 1990, The Journal of thoracic and cardiovascular surgery.

[14]  M. Fagerhol,et al.  A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. , 1989, The Journal of rheumatology.

[15]  R. Larsson,et al.  The Search for Thromboresistance Using Immobilized Heparin , 1987, Annals of the New York Academy of Sciences.

[16]  S. Frøland,et al.  Quantification of the Terminal Complement Complex in Human Plasma by an Enzyme‐Linked Immunosorbent Assay Based on Monoclonal Antibodies against a Neoantigen of the Complex , 1985, Scandinavian journal of immunology.

[17]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.

[18]  D. Stroncek,et al.  Complement activation and neutropenia occurring during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[19]  J. Heremans,et al.  Immunochemical quantitation of antigens by single radial immunodiffusion. , 1965, Immunochemistry.

[20]  B. Nilsson,et al.  Complement activation by polymethyl methacrylate minimized by end-point heparin attachment. , 1993, Biomaterials.

[21]  H. Hansson,et al.  Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. , 1992, Scandinavian journal of thoracic and cardiovascular surgery.

[22]  A. Semb,et al.  Cardiac surgery and distribution of the leukocyte L1 protein-calprotectin. , 1991, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[23]  M. Turina,et al.  Reduced blood loss and transfusion requirements with low systemic heparinization: preliminary clinical results in coronary artery revascularization. , 1990, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  M. Kazatchkine,et al.  Biocompatibility of extracorporeal circuits in heart surgery. , 1990, Transfusion science.

[25]  R. Colman,et al.  Platelet and neutrophil activation in cardiopulmonary bypass. , 1990, The Annals of thoracic surgery.

[26]  I. Brandslund,et al.  Neutrophil lysosomal enzyme release and complement activation during cardiopulmonary bypass. , 1987, Scandinavian journal of thoracic and cardiovascular surgery.

[27]  J. Bakken,et al.  Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein. , 1984, Scandinavian journal of clinical and laboratory investigation.

[28]  R. Larsson,et al.  A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.